Physician

Paolo Carlo Colombo, M.D.

According to 2025 Medicare claims, Paolo Colombo, M.D. (NPI: 1336226810) practices advanced heart failure and transplant cardiology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (NPI: 1861907321; TIN: 135598093) and primary practice location at 10032-3739. Colombo is affiliated with the NewYork Quality Care (ACO ID: A2571), participating under the MSSP model.

Colombo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 206 traditional Medicare patients, billed 734 HCPCS/CPT codes, and received $73,902 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 482 prescription claims across 70 beneficiaries totaling $497,495 in drug costs, led by Vyndamax (Tafamidis). DME data shows 214 claims. Open Payments data shows 29 records totaling $3,857. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $270,238 and ending at $497,495. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,253 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	159	584	$67,926
2016	157	626	$78,705
2017	131	444	$48,585
2018	127	476	$60,704
2019	155	636	$81,283
2020	147	657	$68,550
2021	190	895	$82,540
2022	182	741	$69,686
2023	164	840	$75,147
2024	206	734	$73,902

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	19	96	$270,238
2016	N/R	32	$292,285
2017	N/R	52	$335,107
2018	N/R	33	$331,782
2019	N/R	46	$529,720
2020	11	36	$199,241
2021	16	44	$4,774
2022	61	409	$194,907
2023	80	657	$830,633
2024	70	482	$497,495

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	90	$71,969
2016	N/R	256	$93,179
2017	N/R	N/R	N/R
2018	N/R	22	$2,738
2019	N/R	68	$6,234
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	24	$3,066
2023	N/R	62	$920
2024	N/R	214	$5,117

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	26	103	$200
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	39	55	$168
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	89	154	$113
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	47	139	$74
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	57	89	$15

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	11	330	$238,785
Everolimus	Everolimus	17	990	$38,881
Entresto	Sacubitril/Valsartan	13	980	$21,059
Daptomycin	Daptomycin	29	195	$16,609
Mycophenolate Mofetil	Mycophenolate Mofetil	17	1,445	$6,453

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	55	$2,913
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	78	$1,078
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	31	$583
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	39	$536
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$6

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$3,857	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paolo Carlo Colombo, M.D.?

Tedicare shows public-source Medicare data for Paolo Carlo Colombo, M.D. (NPI 1336226810), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paolo Carlo Colombo, M.D. have ACO affiliation data?

Paolo Carlo Colombo, M.D. is shown with ACO affiliation data for NewYork Quality Care (MSSP, ACO ID A2571).

What billing organization is linked to Paolo Carlo Colombo, M.D.?

Paolo Carlo Colombo, M.D. is linked to TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (billing NPI 1861907321) in the available physician profile data.

Does Paolo Carlo Colombo, M.D. have Open Payments data?

Paolo Carlo Colombo, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.